SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01936051

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients

To modeling the pharmacokinetic-pharmacodynamic(PK-PD) simulation with the plasma concentration and the transporter occupancy from OCD patients treated with escitalopram. To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the PK-PD modeling in OCD patients treated with escitalopram.

NCT01936051 OCD
MeSH:Compulsive Personality Disorder Obsessive-Compulsive Disorder
HPO:Obsessive-compulsive behavior


Primary Outcomes

Measure: serotonin transporter occupancy

Time: 72hr after oral administration of escitalopram

Secondary Outcomes

Measure: genotype

Time: baseline

Description: scale for the severity of Obsessive-compulsive symptoms

Measure: Yale-Brown Obsessive Compulsive Scale(Y-BOCS) Score

Time: baseline

Description: serotonin transporter occupancy measured at 5 hour and 24 hour after oral dose of escitalopram

Measure: serotonin transporter occupancy

Time: within the first 24hrs after oral administration of escitalopram

Description: plasma concentration of escitalopram at baseline, 1, 2, 3, 5, 8, 10, 24, 48, 72 hour after oral dose of escitalopram

Measure: escitalopram plasma concentration

Time: within 72 hours after oral administration of escitalopram

Time Perspective: Other

Other


There is one SNP

SNPs


1 G2677T

To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the PK-PD modeling in OCD patients treated with escitalopram. --- G2677T ---

To genotype G2677T/A SNP of ABCB1 gene in OCD patients treated with escitalopram. --- G2677T ---



HPO Nodes


HPO: